Aug 6 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O :
* ACADIA PHARMACEUTICALS AND NEUREN PHARMACEUTICALS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR THE NORTH AMERICAN DEVELOPMENT AND COMMERCIALIZATION OF TROFINETIDE IN RETT SYNDROME
* ACADIA PHARMACEUTICALS INC - -NEUREN TO RECEIVE US $10 MILLION UPFRONT PLUS POTENTIAL MILESTONES OF UP TO US $455 MILLION AND ROYALTIES
* ACADIA PHARMACEUTICALS INC - NEUREN RETAINS ALL RIGHTS TO TROFINETIDE OUTSIDE OF NORTH AMERICA
* ACADIA PHARMACEUTICALS - PLANS TO INITIATE PHASE 3 STUDY OF TROFINETIDE FOR TREATMENT OF RETT SYNDROME IN SECOND HALF OF 2019
* ACADIA PHARMACEUTICALS - POTENTIAL MILESTONE PAYMENTS TO NEUREN CONSIST OF $105 MILLION SUBJECT TO ACHIEVEMENT OF DEVELOPMENT MILESTONES IN RETT SYNDROME